Top Medical News
Roshini Claire Anthony, 3 days ago

Young colorectal cancer patients tend to present with acute, relatively vague symptoms and advanced disease, according to a single-centre study from Singapore.

Pearl Toh, 3 days ago
The next-generation ALK inhibitor brigatinib yielded high and durable responses in both whole-body and intracranial endpoints, with a median progression-free survival (PFS) of over 1 year in patients with ALK-positive non-small cell lung cancer (NSCLC) whose disease had progressed after crizotinib, according to the ALTA* trial.
Tristan Manalac, 3 days ago
Chronic hepatitis C patients with sustained virological response (SVR) after treatment may still be at risk of hepatocellular carcinoma (HCC), a new study reports. Risk factors include a lower platelet count, cirrhosis and elevated aspartate aminotransferase (AST) levels.
Stephen Padilla, 4 days ago
Combined treatment with aspirin and clopidogrel is at least as safe as prolonged aspirin use regarding the risk of cancer, according to a recent study, which supports the hypothesis that clopidogrel use may reduce cancer incidence.
Naomi Rodrig, 5 days ago

Two Swedish national registry studies presented at the European League Against Rheumatism (EULAR) Annual Congress 2017 suggest no increased cancer risk for rheumatoid arthritis (RA) patients treated with biological disease-modifying anti-rheumatic drugs (bDMARDs), including tumour necrosis factor (TNF) inhibitors. 

5 days ago
Obesity is associated with greater risk for unfavourable pathological features in men with low risk prostate cancer who are eligible for active surveillance, according to a study. Obese men are likely to have transition zone cancer, which is related to unfavourable pathology findings in those with very low risk prostate cancer.
Dr. Joseph Delano Fule Robles, 6 days ago

The experimental targeted therapy, enasidenib, an oral selective inhibitor of mutated IDH2 enzymes developed for the treatment of acute myeloid leukaemia (AML), has demonstrated maturation of blasts to neutrophils with resultant prolongation of survival in treatment-resistant patients with mutant-IDH2 AML in an early trial. 

Special Reports
Prof. Ignatius Ou Sai Hong, Dr. James Suh, Dr. Wong Seng Weng, Dr. Amit Verma, 14 May 2017
As targeted cancer therapy options are increasing, it is becoming more important to choose the most appropriate treatment for patients with cancer. At a Roche-sponsored symposium held during the 2nd ESMO Asia Congress in Singapore, four experts discussed the potential of comprehensive genomic profiling (CGP) for personalizing cancer care and helping healthcare professionals to make the best treatment decisions for individual patients.
Dr. Ross Soo, Prof. James Chih-Hsin Yang, Prof. Tony Mok, Prof. Fred Hirsch, 28 Mar 2017
Classification and treatment of non-small cell lung cancer (NSCLC) has greatly evolved in recent years. A better understanding of this complex malignancy has led to a shift from histologic diagnosis to more accurate subclassification using molecular screening which, in turn, led to the transition from empiric treatment to molecular target therapy. At the European Society for Medical Oncology (ESMO) Asia 2016 Congress in Singapore, Dr Ross Soo from the National University Cancer Institute, Singapore, Professor James Chih-Hsin Yang from the National Taiwan University Hospital, Taiwan, Professor Tony Mok from The Chinese University of Hong Kong, Hong Kong, and Professor Fred Hirsch from the University of Colorado Cancer Center, Colorado, US presented therapeutic biomarker-driven strategies for improving outcomes in patients with NSCLC. The discussion focused on the role and impact of molecular target therapy using epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) biomarkers and T-cell-based immunotherapy in coming up with algorithms to guide clinicians in selecting the best treatment regimen for each patient.
14 Mar 2017
Over 20 leading surgical and medical oncologists from Singapore attended a dinner meeting on the Neoadjuvant treatment of early breast cancer (eBC). Co-chaired by Dr Veronique Tan (National Cancer Centre, Singapore) and Dr Elaine Lim (National Cancer Centre, Singapore), the meeting served as a platform to discuss the role of neoadjuvant therapy in eBC management. Guest speakers, Professor J. Michael Dixon OBE (Edinburgh Breast Unit, Western General Hospital, Edinburgh, United Kingdom) and Dr Rebecca Dent (National Cancer Centre, Singapore) shared their perspectives on the benefits of neoadjuvant therapy in different BC subtypes.
31 Jan 2017
At the launch of Caris Molecular Intelligence® in Malaysia, Dr Andrew Dean, Head of Oncology at the St John of God Subianco Hospital, Perth, shared with the audience on molecular profiling and its benefits, with a focus on the Caris Molecular Intelligence® service.
16 Dec 2016
KEYTRUDA – Pembrolizumab 100 mg/4 mL soln for inj – Merck Sharp & Dohme
Yao-Hua Law, PhD, 15 Dec 2016
The genomics of cancer patients affect their responses to therapies. Some genomic alterations in cancer genes are better treated with targeted therapies, and physicians informed by genomic profiles of their patients can better decide on optimal treatments. Next-generation sequencing (NGS) technology has facilitated rapid and inexpensive gene sequencing for clinical use. This article discusses NGS applications for cancer management, focusing on comprehensive genomic profiling (CGP).
Jairia Dela Cruz, 06 Dec 2016
Sorafenib appears to be well-tolerated in patients with hepatocellular carcinoma (HCC), with the subgroup of Child-Pugh B patients having a shorter treatment duration and higher serious adverse event (SAE) incidence, according to the results of a subgroup analysis of GIDEON*.
Conference Reports
Elvira Manzano, 14 Jun 2017
The oral PARP inhibitor olaparib significantly improved progression-free survival (PFS) in women with BRCA-positive, HER2-negative breast cancer compared with standard chemotherapy in the phase III OlympiAD* trial, ushering in a new era of hope in BRCA-mutated breast cancer.
Audrey Abella, 13 Jun 2017
A psychological intervention, Conquer Fear, may help alleviate fear of cancer recurrence (FCR) in cancer survivors, according to a study presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2017 held in Chicago, Illinois, US.
Elvira Manzano, 12 Jun 2017
Three vs 6 months of adjuvant oxaliplatin-based chemotherapy may be sufficient for colon cancer with low risk of recurrence and has the advantage of fewer side effects, according to the IDEA* trial which pooled data from six phase III trials.
Roshini Claire Anthony, 12 Jun 2017

The second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) dacomitinib improved progression-free survival (PFS) by an additional 5 months compared with gefitinib in patients with EGFR-positive non-small cell lung cancer (NSCLC), according to results of the open-label, phase III ARCHER 1050* trial.

Pearl Toh, 10 Jun 2017
Larotrectinib delivers durable response across diverse cancer types, including paediatric and adult cancers, according to an interim analysis of three ongoing trials presented at the ASCO 2017 Annual Meeting.
Roshini Claire Anthony, 09 Jun 2017

Selective internal radiation therapy (SIRT) did not fare better than sorafenib in terms of overall survival (OS) in patients with locally advanced hepatocellular carcinoma (HCC), though it appeared to be associated with fewer total adverse events, according to findings of the phase III, multicentre (11 Asia-Pacific countries), open-label SIRveNIB* study.

Elaine Soliven, 09 Jun 2017
The incidence of chronic disease among childhood cancer survivors has decreased over the past decades, likely due to advances in treatment, according to a study presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO 2017) held in Chicago, Illinois, US.
Product Highlights
CME Modules
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
DOWNLOAD